A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19)

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan

(2020) Shao-Chung Cheng et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

(2020) Timothy P. Sheahan et al.   Nature Communications

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

(2020) Vanessa Monteil et al.   CELL

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

(2020) Evangelos J. Giamarellos-Bourboulis et al.   Cell Host & Microbe

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

(2020) Jianjun Gao et al.   BioScience Trends

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study

(2020) Philippe Gautret et al.   Travel Medicine and Infectious Disease

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

(2020) Wei Tang et al.   BMJ-British Medical Journal

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

(2020) Mandeep R Mehra et al.   LANCET

Current targeted therapeutics against COVID-19: Based on first-line experience in China

(2020) Yue Zhang et al.   PHARMACOLOGICAL RESEARCH

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

(2020) Mayla Gabriela Silva Borba et al.   JAMA Network Open

Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase

(2017) Yousuke FURUTA et al.   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences